Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol

Journal of Clinical Oncology

Volumn 14, Issue 8, 1996, Pages 2250-2257

  Chang, A ^a   Yeap, B ^a   Davis, T ^a   Blum, R ^a   Hahn, R ^a   Khanna, O ^a   Fisher, H ^a   Rosenthal, J ^a   Witte, R ^a   Schinella, R ^a   Trump, D ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; FLUTAMIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER HORMONE THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GYNECOMASTIA; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 9444292850     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.8.2250     Document Type: Article

References (33)

1. Higgins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941
2. Perez CA, Fair WR, Ihde DC: Carcinoma of the prostate, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 3). Philadelphia, PA, Lippincott, 1989, pp 1049-1052
3. Grayhack JT, Keeler TC, Kozlowski JM: Carcinoma of the prostate: Hormonal therapy. Cancer 60:589-601, 1987
4. Venner PM: Therapeutic options in treatment of advanced carcinoma of the prostate. Semin Oncol 17:73-77, 1990 (suppl 9)
5. Byar DP: The Veteran Administration Cooperative Urologic Research Group's studies of cancer of the prostate. Cancer 32:1126-1130, 1973
6. Shearer RJ, Hendry WF, Sommerville IF, et al: Plasma testosterone: An accurate monitor of hormone treatment of prostatic cancer. Br J Urol 45:668-677, 1973
7. Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. N Engl J Med 311:1281-1286, 1984
8. deVoogt HJ, Smith PH, Pavone-Macaluso M et al: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate, and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from EORTC trials 30761 and 30762. J Urol 135:303-307, 1986
9. Neri R, Florance K, Koziol P, Van Cleave S: A biological profile of a non-steroidal anti-androgen, SCH 13521. Endocrinology 91:427-437, 1972
10. Liao S, Howell DK, Chang TM: Action of a non-steroidal antiandrogen, flutamide, on a receptor binding and nuclear retention of 5-alpha-dihydrotestosterone in rat ventral prostate. Endocrinol 94:1205-1209, 1974
11. Sogani PC, Vagaiwala MR, Whitmore WF: Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 54:744-750, 1984
12. Di Silverio F, Tenaglia R, Bizzarri M, et al: Experience with flutamide in advanced prostatic cancer patients refractory to previous endocrine therapy. J Drug Dev 1:10-16, 1987 (suppl 1)
13. Pavone-Macaluso M, Pavone C, Serretta V, et al: Antiandrogens alone or in combination for treatment of prostate cancer: The European experience. Urology 34:27-36, 1989 (suppl 4)
14. Prout GR, Keating MA, Griffin PP, et al: Long-term experience with flutamide in patients with prostatic carcinoma. Urology 34:37-45, 1989 (suppl 4)
15. Jacobo E, Schmidt JD, Weinstein SH, et al: Comparison of flutamide (SCH 13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology 8:231-233, 1976
16. Oken MM, Creech RM, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
17. Cox DR: Analysis of Binary Data. London, United Kingdom, Chapman & Hall, 1970
18. Mehta CR, Patel NR, Tsiatis AA: Exact significance of testing to establish treatment equivalence with ordered categorical data. Biometrics 40:819-825, 1984
19. Kaplan EL, Meier P: Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
21. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-202, 1972
22. Byar DP, Green SB: The choice of treatment for cancer patients based on covariate information. Bull Cancer 67:477-490, 1980
23. Peeling WB: Phase III studies to compare goseralin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 33:45-52, 1989 (suppl 5)
24. Pavone-Macaluso M, deVoogt HJ, Viggiano G, et al: Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: Final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 136 624-631, 1986
25. Crawford ED, Eisenberger MA, McLeod DG, et al: A control trial of leuprolide with and without flutamide in prostatic cancer. N Engl J Med 321:419-424, 1989
26. Neri R: Clinical utility of flutamide. J Drug Dev 1:5-9, 1987 (suppl 1)
27. Lund F, Rasmussen F: Flutamide versus stilbestrol in the management of advanced prostatic cancer. Br J Urol 61:140-142, 1988
28. Cassileth BR, Salowny MS, Vogelzang NJ, et al: Patients' choice of treatment in stage D prostate cancer. Urology 33:47-62, 1989 (suppl 5)
29. Fair WR: Hormonal therapy of advanced prostatic cancer. J Urol 136:653-654, 1986
30. Delaere KPJ, Van Thillo EL: Flutamide monotherapy as primary treatment in advanced prostate carcinoma. Semin Oncol 18:13-18, 1991 (suppl 6)
31. Kennealy GT, Furr BJ: Use of the non-steroidal anti-androgen casodex in advanced prostate carcinoma. Urol Clin North Am 18:99-110, 1991
32. Decensi A, Guarneri D, Paoletti MC, et al: Phase II study of the pure non-steroidal anti-androgen nilutamide in prostatic cancer: Italian Prostate Cancer Project (PONCAP). Eur J Cancer 27:1100-1104, 1991
33. Sharifi R, Chodak G, Venner P, et al: Casodex versus castration in treatment of stage D2 prostate cancer: Prostate specific antigen (PSA) as a measure of outcome. Proc Am Soc Clin Oncol 12:241, 1993 (abstr)